| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.047 | 0.1 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | 0.057 | 0.1 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | -0.06 | 0.1 |
| mRNA | BRD-K71935468 | CTRPv2 | pan-cancer | AAC | 0.062 | 0.1 |
| mRNA | SMER-3 | CTRPv2 | pan-cancer | AAC | 0.063 | 0.1 |
| mRNA | CX-5461 | GDSC1000 | pan-cancer | AAC | -0.053 | 0.1 |
| mRNA | NVP-BEZ235 | GDSC1000 | pan-cancer | AAC | 0.059 | 0.1 |
| mRNA | TGX221 | GDSC1000 | pan-cancer | AAC | 0.082 | 0.1 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | 0.06 | 0.1 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.06 | 0.1 |